Directorio

This study has two parts. In the first part, people will be placed into one of three groups by chance. They may receive two doses of a study medicine called SAR447189, one dose of the study medicine and one dose of a placebo, or two doses of a placebo over about forty weeks. After this part, some people may be able to continue into the second part of the study, where everyone will receive the study medicine for a longer time. The full study can last several years. During this time, participants will have many clinic visits. At these visits, doctors will do tests such as heart checks, blood tests, procedures to look inside the body, and ask questions about health and how the person feels.

We are doing this study to find out if an investigational, non-stimulant drug called SPN-812 (the study drug, viloxazine extended-release capsules). The study drug is FDA-approved for children ages 6 and above. It is not approved for children younger than 6, so this study is being done to determine how well it works and how safe it is for preschool-aged children.

We are doing this study to find out if an experimental drug called mosunetuzumab (the study drug) is a safe and effective option for low burden follicular lymphoma. We want to know how well it works in comparison to rituximab, which is the standard drug used to treat people with this diagnosis.

The SYNCHRONICITY study is a test to compare two treatments for people with heart failure and a heart electrical problem called left bundle branch block. People in the study will be randomly chosen to get one of two devices: a new type called LBBAP or a regular type called CRT. First, they will have surgery to put in the device. Then, they will have checkups at 6 months, 12 months, and once a year for up to 5 years. At these visits, doctors will check the device, do heart tests, and ask how the person feels. The study wants to find out which device is safer and works better.

We are doing this study to help connect people with type 1 diabetes to research studies they may be eligible to join as participants.

We are doing this study to find out if an experimental drug called mezagitamab (the study drug) is a safe and effective option for people with chronic primary immune thrombocytopenia (ITP). We want to know if adding the study drug to someone's current treatment has any benefit.